Clinerion Ltd Contact Details:
Main address: Margarethenstrasse 47 4053 Basel, Switzerland ,
Tel:+41 61 865 60 60 , E-mail: info(at) Website:

Clinerion Patient Network Explorer

Clinerion Patient Network Explorer

Optimized study design, precise site selection and faster patient search and identification for clinical research - in real time.

Clinerion Cookie Policy

Welcome to the Clinerion website. This website uses cookies. These cookies are used on your browser to understand how you are using our website. Using this website means you agree to our use of cookies. If you prefer not to have these cookies on your device, we advise you to disable them in your web browser settings. You accept the use of cookies by accepting this notice. You can read more details via our Privacy Policy page.

Privacy Policy page >

Webinar: Hematologic Cancers and Gene-Based “Tumor Agnostic” Therapies

Galien Week of Innovation, Pharma Webinar 1

Date: Wednesday, October 27, 2021
Time: 10 am ET | 4 pm CET

Clinerion CEO Baris Erdogan will chair this webinar run by the Galien Foundation.

Will the success of novel, gene-based therapies in advancing survival timelines in blood and bone marrow cancers be repeated in the solid tumor setting, with therapies that address each tumor’s individual genetic profile rather than association with its geographic location in the body?


Dr. Barış Erdoğan
Clinerion Ltd

Barış Erdoğan studied computer engineering and holds an M.Sc. and Ph.D. in educational technology. He practiced data mining techniques in various sectors including healthcare. He lectures on the topics of software development, database management, medical informatics, and project management. His expertise and experience include the management of innovative Medical Informatics projects and implementation of end-to-end Healthcare IT enterprise information systems, both in the public and private sectors


Shefali Agarwal, MD, MPH, MBA
Chief Medical and Development Officer and trained medical oncologist

Shefali Agarwal, M.D., MPH, MBA, is Epizyme’s Chief Medical & Development Officer and a trained medical oncologist. Dr. Agarwal served as Chief Medical Officer at SQZ Biotech, where she built and led clinical development, including clinical research operations and regulatory functions. Shefali also held leadership positions at Curis and Tesaro.  She also serves on the on the Board of Directors for FATE, Gritstone Bio and ITB-Med and Onexo where she is the Chair.

Dr. Agarwal was a recipient of the 17th Annual 20 Outstanding Women of the Year award for the year 2019 from INDIA New England News, and invited panelist speaker of Chief Medical Officer Summit 360˚.

Dr. Michael G. Kauffman, M.D., PhD
Chief Executive Officer and Co-Founder
Karyopharm Therapeutics Inc.

Dr. Kauffman co-founded Karyopharm Therapeutics with Dr. Sharon Shacham in 2008 and served as the Chief Executive Officer from January 2011 to April 2021, as Chief Medical Officer from December 2012 to July 2019, and as a director since 2008. He is currently Senior Clinical Advisor and helps guide clinical development for Karyopharm’s robust pipeline, with an increasing focus on solid tumor indications.

Dr. Kauffman received a Bachelor of Arts in Biochemistry from Amherst College, a Doctor of Medicine and Doctor of Philosophy from Johns Hopkins Medical School, and trained in internal medicine and rheumatology at Beth Israel (now Beth Israel Deaconness Medical Center) and Massachusetts General Hospitals. He is board certified in internal medicine.

Mark Mogul
Head of Medical Affairs
Servier Pharmaceuticals

Mark Mogul, MD, serves as the Head of Medical Affairs at Servier Pharmaceuticals. Mark earned his medical degree from the SUNY Health Science Center at Syracuse, completed a fellowship in Pediatric Hematology-Oncology at Stanford University, and a Bone Marrow Transplant Fellowship at the Fred Hutchinson Center in Seattle, Washington. Prior to joining Servier, Mark worked as a Pediatric Hematologist-Oncologist for 27 years, and in 2018, was recognized as one of Tampa Magazine’s “Best Physicians.”

Dr. Iain Webb, MD FRCPC
Head of US Medical Affairs
Bayer Oncology

Iain is Vice President and Head, US Medical Affairs, Oncology at Bayer.  Prior to joining Bayer, Iain held various Medical Affairs and Clinical Development roles at Millennium Pharmaceuticals, Takeda Oncology and Pfizer.  Previously, he was an Attending Physician at the Dana-Farber Cancer Institute.  Iain obtained his M.D. degree from McGill University in Montreal, Canada, then completed internal medicine residency and hematology fellowship at McGill University, and hematology/oncology fellowship at Beth Israel Hospital Boston/Dana-Farber Cancer Institute.

Click here for more information on the Galien Week >